Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 basket trial of IOV-5001.

Next Previous
Trial Profile

A Phase 1/2 basket trial of IOV-5001.

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 24 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IOV 5001 (Primary)
  • Indications Colorectal cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions
  • Acronyms basket trial

Most Recent Events

  • 07 May 2026 According to Iovance Biotherapeutics media release, an Investigational New Drug (IND) application was submitted to FDA to begin enrolling in second half of 2026.
  • 05 Mar 2026 New trial record
  • 24 Feb 2026 According to Iovance Biotherapeutics media release, Investigational New Drug (IND) submission is planned in the first half of 2026 to begin clinical development of IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 TIL therapy, in a Phase 1/2 basket trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top